Search - tctmd.com

Displaying 941 - 960 of 6835

Sort: Relevancy | Date

Presentation THT 2025

Management of Clinically Stable Patients With Impella 5.5 on a Cardiac Stepdown Unit Is Associated With Low Adverse Event Rates and Lower Hospital Costs

Presenter: Anthony Carnicelli

February 11, 2025

Presentation THT 2025

Effect of Vericiguat on Pulmonary Artery Pressures in Heart Failure Patients: Insights From Pressure Sensor Monitoring

Presenter: Boaz Elad

February 11, 2025

Presentation THT 2025

Relationship Between Changes in Pulmonary Artery Pressure, Blood Pressure and Weight in Response to Titration of Heart Failure Medications During Ambulatory Monitoring

Presenter: Sandip Zalawadiya

February 11, 2025

Presentation THT 2025

Baroreflex Activation Therapy Improves Cardiopulmonary Exercise Tolerance and Aerobic Capacity in Heart Failure With Reduced Ejection Fraction

Presenter: Dmitry Yaranov

February 11, 2025

Presentation THT 2025

Comparative Outcomes of Veno-Arterial ECMO (VA-ECMO) vs. IMPELLA vs. Combining VA-ECMO With IMPELLA (ECPELLA) in Cardiogenic Shock

Presenter: Tahira Qadeer

February 11, 2025

Presentation THT 2025

Association of Temporary Mechanical Circulatory Support With Allosensitization and Cardiac Transplant Outcomes

Presenter: Jason Feinman

February 11, 2025

Presentation THT 2025

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 11, 2025

Presentation THT 2025

Winning the War on Shock: Insights From the Premier Database

Presenter: Joseph Ibrahim

February 11, 2025

Presentation THT 2025

Determining Equity and Timeliness of ATTR-CM Diagnosis

Presenter: Anubodh Varshney

February 11, 2025

Presentation THT 2025

Disparities in MDD Incidence Between HFpEF and HFrEF Patients

Presenter: Ibrahim Kamel

February 11, 2025

Presentation THT 2025

Evaluating the Impact of Sglt2 Inhibitors on Outcomes in Patients With Sarcoidosis and Heart Failure With Preserved Ejection Fraction

Presenter: Emmanuel Otabor

February 11, 2025

Presentation THT 2025

Welcome

Presenter: Daniel Burkhoff

February 11, 2025

Presentation THT 2025

Shaping the Future of Heart Failure

Presenter: Anu Lala-Trindade (Lala)

February 11, 2025

Presentation THT 2025

Cardiac Microcurrent Application for the Reversal of Heart Failure

Presenter: Eduardo Rame

February 11, 2025

Presentation THT 2025

Atrial Shunt for Heart Failure With Preserved and Mildly Reduced Ejection Fraction: Five-Year Outcomes in the REDUCE LAP-HF II Trial

Presenter: Sanjiv Shah

February 11, 2025

Presentation THT 2025

Right Ventricular to Pulmonary Artery Coupling and Clinical Outcomes After Interatrial Shunting in Heart Failure

Presenter: Stefan Anker

February 11, 2025

Presentation THT 2025

Duration of Heart Failure, Cardiac Dysfunction and Remodeling, and Response to Atrial Shunt Treatment in HFpEF and HFmrEF

Presenter: Barry Borlaug

February 11, 2025

Presentation THT 2025

Con

Presenter: Zachary Cox

February 11, 2025

Presentation THT 2025

Pro

Presenter: Wendy McCallum

February 11, 2025

Presentation THT 2025

Left Bundle Branch Area Pacing: Implications for Long Term LV Function in Heart Failure

Presenter: Brett Atwater

February 11, 2025

Advertisement

Management of Clinically Stable Patients With Impella 5.5 on a Cardiac Stepdown Unit Is Associated With Low Adverse Event Rates and Lower Hospital Costs

Effect of Vericiguat on Pulmonary Artery Pressures in Heart Failure Patients: Insights From Pressure Sensor Monitoring

Relationship Between Changes in Pulmonary Artery Pressure, Blood Pressure and Weight in Response to Titration of Heart Failure Medications During Ambulatory Monitoring

Baroreflex Activation Therapy Improves Cardiopulmonary Exercise Tolerance and Aerobic Capacity in Heart Failure With Reduced Ejection Fraction

Comparative Outcomes of Veno-Arterial ECMO (VA-ECMO) vs. IMPELLA vs. Combining VA-ECMO With IMPELLA (ECPELLA) in Cardiogenic Shock

Association of Temporary Mechanical Circulatory Support With Allosensitization and Cardiac Transplant Outcomes

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Winning the War on Shock: Insights From the Premier Database

Determining Equity and Timeliness of ATTR-CM Diagnosis

Disparities in MDD Incidence Between HFpEF and HFrEF Patients

Evaluating the Impact of Sglt2 Inhibitors on Outcomes in Patients With Sarcoidosis and Heart Failure With Preserved Ejection Fraction

Welcome

Shaping the Future of Heart Failure

Cardiac Microcurrent Application for the Reversal of Heart Failure

Atrial Shunt for Heart Failure With Preserved and Mildly Reduced Ejection Fraction: Five-Year Outcomes in the REDUCE LAP-HF II Trial

Right Ventricular to Pulmonary Artery Coupling and Clinical Outcomes After Interatrial Shunting in Heart Failure

Duration of Heart Failure, Cardiac Dysfunction and Remodeling, and Response to Atrial Shunt Treatment in HFpEF and HFmrEF

Con

Pro

Left Bundle Branch Area Pacing: Implications for Long Term LV Function in Heart Failure

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content